The Bell2Bell (B2B) Podcast

Bell2Bell’s latest podcast features Brien Lundin, CEO of New Orleans Investment Conference and Editor of Gold Newsletter. The New Orleans Investment Conference, scheduled for November 1-3, 2023, brings together the world’s most sophisticated investors to discover new opportunities and strategies, exchange ideas, plan for the coming year and enjoy the camaraderie of like-minded individuals.

Throughout the interview, Lundin provided intriguing insights into the history of the New Orleans Investment Conference and highlights planned for this year’s event.

“The New Orleans Investment Conference is the longest-running investment event in the world today. This will be our 49th year,” Lundin said. “It has also earned a reputation over the years of being ‘The World’s Greatest Investment Event’. We’re known for bringing together speakers and experts, including some of the world’s leading thought-leaders in macroeconomics, various investment markets and even geopolitics.”

“Our stage has been graced by the likes of Lady Margaret Thacher, Ayn Rand, Milton Friedman and Alan Greenspan. The list goes on and on and features many of the giants of modern history, economics and geopolitics. This year, we have what I believe is the greatest lineup of experts in our history and, by extension, in the history of any investment event. We’ve got people who can explain the very unusual and extraordinary events that are going on in geopolitics and economics. Because of this extraordinary environment that we’re in right now, extraordinary thinkers have risen to the fore, and we’ve got them all.”

“Anybody who is a serious investor should attend the New Orleans Investment Conference, including anyone who is concerned about a world in which the levers of the economy are being pulled by central bankers almost exclusively… For anyone who believes that the coming events are either risks to their wealth or opportunities to build their wealth, both sides will be presented at our event. These are unusual times that we’re living through… and a number of things are going to be breaking in the days and weeks ahead. If you’re concerned about that, this is the place for you.”

Join IBN’s Jonathan Keim and Bell2Bell’s latest guest to learn more about the investment opportunities available to attendees of this well-recognized event series.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN wherever published or re-published: http://ibn.fm/Disclaimer

Bell2Bell’s latest podcast features Brien Lundin, CEO of New Orleans Investment Conference and Editor of Gold Newsletter. The New Orleans Investment Conference, scheduled for November 1-3, 2023, brings together the world’s most sophisticated investors to discover new opportunities and strategies, exchange ideas, plan for the coming year and enjoy the camaraderie of like-minded individuals.

Throughout the interview, Lundin provided intriguing insights into the history of the New Orleans Investment Conference and highlights planned for this year’s event.

“The New Orleans Investment Conference is the longest-running investment event in the world today. This will be our 49th year,” Lundin said. “It has also earned a reputation over the years of being ‘The World’s Greatest Investment Event’. We’re known for bringing together speakers and experts, including some of the world’s leading thought-leaders in macroeconomics, various investment markets and even geopolitics.”

“Our stage has been graced by the likes of Lady Margaret Thacher, Ayn Rand, Milton Friedman and Alan Greenspan. The list goes on and on and features many of the giants of modern history, economics and geopolitics. This year, we have what I believe is the greatest lineup of experts in our history and, by extension, in the history of any investment event. We’ve got people who can explain the very unusual and extraordinary events that are going on in geopolitics and economics. Because of this extraordinary environment that we’re in right now, extraordinary thinkers have risen to the fore, and we’ve got them all.”

“Anybody who is a serious investor should attend the New Orleans Investment Conference, including anyone who is concerned about a world in which the levers of the economy are being pulled by central bankers almost exclusively… For anyone who believes that the coming events are either risks to their wealth or opportunities to build their wealth, both sides will be presented at our event. These are unusual times that we’re living through… and a number of things are going to be breaking in the days and weeks ahead. If you’re concerned about that, this is the place for you.”

Join IBN’s Jonathan Keim and Bell2Bell’s latest guest to learn more about the investment opportunities available to attendees of this well-recognized event series.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN wherever published or re-published: http://ibn.fm/Disclaimer

“Reunion Gold is a gold exploration company. Our activities are mainly focused around the Guiana Shield, which includes countries like French Guiana, Suriname and Guyana,” said Rick Howes, President & CEO of Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF). “We’ve been well established in [Guyana], and the team that’s leading the company today includes individuals who have been based in the Guiana Shield for over 40 years now… It’s a relatively underdeveloped, underexplored region, and it has high prospectivity, as it forms the basis of a large greenstone belt, which is a very common [source] for gold deposits.”

“Reunion Gold is a gold exploration company. Our activities are mainly focused around the Guiana Shield, which includes countries like French Guiana, Suriname and Guyana,” said Rick Howes, President & CEO of Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF). “We’ve been well established in [Guyana], and the team that’s leading the company today includes individuals who have been based in the Guiana Shield for over 40 years now… It’s a relatively underdeveloped, underexplored region, and it has high prospectivity, as it forms the basis of a large greenstone belt, which is a very common [source] for gold deposits.”

Bell2Bell’s latest podcast features Tyrone Docherty, President & CEO of First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF), a company committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. 

To begin the interview, Docherty provided an introduction to the company’s business model and operating markets. 

“First Tellurium has a wonderful, high-grade gold and silver property in Canada, but it comes with this unique mineral, Tellurium, which is listed by both the United States and Canadian governments as critical,” said Docherty. “Tellurium has come into the fore over the last couple of decades, because it is used in solar panels by U.S. corporation First Solar, which uses a mixture of cadmium and tellurium, as opposed to different solar panels coming out of China. Tellurium is very important there, and it’s a very rare metal.” 

Bell2Bell’s latest podcast features Tyrone Docherty, President & CEO of First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF), a company committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. 

To begin the interview, Docherty provided an introduction to the company’s business model and operating markets. 

“First Tellurium has a wonderful, high-grade gold and silver property in Canada, but it comes with this unique mineral, Tellurium, which is listed by both the United States and Canadian governments as critical,” said Docherty. “Tellurium has come into the fore over the last couple of decades, because it is used in solar panels by U.S. corporation First Solar, which uses a mixture of cadmium and tellurium, as opposed to different solar panels coming out of China. Tellurium is very important there, and it’s a very rare metal.” 

Bell2Bell’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV). BiondVax’s pipeline is based on an innovative platform technology of alpaca-derived nanosized antibodies, known as Nanobodies or NanoAbs, addressing infectious and autoimmune diseases with large unmet medical needs such as COVID-19, psoriasis, psoriatic arthritis, asthma and macular degeneration.

This appearance follows a December 2022 interview between Reichman and host Stuart Smith. To review the first part of the series, visit The Stock2Me Podcast.

To begin the latest interview, Reichman discussed the company’s recent achievements, as detailed in a letter to shareholders issued late last year.

“At the end of 2022, we did a round of financing and raised about $8 million. We also started the negotiations to in-license the next antibody from the Max Planck Institute – namely the antibody for targeting interleukin-17 (IL-17) for the treatment of psoriasis,” Reichman said. “We have now in-licensed the IL-17 nanobody. This is a highly promising drug.”

“If we look at the market, psoriatic patients today have several options for treatment. For example, plaque psoriasis patients have creams and other topical drugs, biologics and oral drugs… The topicals are not highly sophisticated drugs to say the least, and they come with a considerable profile of side effects. When a person needs to take steroids once in a while for an infection, they can tolerate it, but when you need to take steroids for an autoimmune disease with chronic inflammation, you create tolerance and deal with potential side effects… The biologics are highly potent, but they are restricted to moderate and severe cases of psoriasis; this accounts for only 15% of patients with psoriasis. The 85% that are left have to choose between drugs based on 1960s and 1970s technology. There hasn’t been much breakthrough in recent years to serve these patients.”

Bell2Bell’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV). BiondVax’s pipeline is based on an innovative platform technology of alpaca-derived nanosized antibodies, known as Nanobodies or NanoAbs, addressing infectious and autoimmune diseases with large unmet medical needs such as COVID-19, psoriasis, psoriatic arthritis, asthma and macular degeneration.

This appearance follows a December 2022 interview between Reichman and host Stuart Smith. To review the first part of the series, visit The Stock2Me Podcast.

To begin the latest interview, Reichman discussed the company’s recent achievements, as detailed in a letter to shareholders issued late last year.

“At the end of 2022, we did a round of financing and raised about $8 million. We also started the negotiations to in-license the next antibody from the Max Planck Institute – namely the antibody for targeting interleukin-17 (IL-17) for the treatment of psoriasis,” Reichman said. “We have now in-licensed the IL-17 nanobody. This is a highly promising drug.”

“If we look at the market, psoriatic patients today have several options for treatment. For example, plaque psoriasis patients have creams and other topical drugs, biologics and oral drugs… The topicals are not highly sophisticated drugs to say the least, and they come with a considerable profile of side effects. When a person needs to take steroids once in a while for an infection, they can tolerate it, but when you need to take steroids for an autoimmune disease with chronic inflammation, you create tolerance and deal with potential side effects… The biologics are highly potent, but they are restricted to moderate and severe cases of psoriasis; this accounts for only 15% of patients with psoriasis. The 85% that are left have to choose between drugs based on 1960s and 1970s technology. There hasn’t been much breakthrough in recent years to serve these patients.”

Bell2Bell’s latest podcast features Chairman, President and CEO Rodney Varner and CFO Ryan Confer of Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. 

In this interview, Varner and Confer discuss the journeys that led them to Genprex and the incredible promise of the company’s clinical drug development pipeline. 

“This work has become a real passion for me. We have the opportunity to do real good here at Genprex on a major scale – helping millions of people around the world with serious diseases through our novel gene therapies,” said Varner. 

Confer then provided some background on what led him to join Genprex in its early days and remain with the company for well over a decade. 

“As I learned more and more about the technology, it became a passion of mine, as well,” said Confer. “What we’re trying to do in cancer – using a lipid-based delivery vehicle and working with tumor suppressor genes that are naturally occurring in the body – represents a treatment paradigm that is unique and different than other options in the space, particularly chemotherapy that has such negative side effects. It is something that we believe really has the potential to change people’s lives as they’re going through such a terrible prognosis. I was excited then, and here we are 12 years later, being able to see it coming through clinical trials, seeing how safe the program has been and seeing the impact that we’re having.” 

Bell2Bell’s latest podcast features Chairman, President and CEO Rodney Varner and CFO Ryan Confer of Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. 

In this interview, Varner and Confer discuss the journeys that led them to Genprex and the incredible promise of the company’s clinical drug development pipeline. 

“This work has become a real passion for me. We have the opportunity to do real good here at Genprex on a major scale – helping millions of people around the world with serious diseases through our novel gene therapies,” said Varner. 

Confer then provided some background on what led him to join Genprex in its early days and remain with the company for well over a decade. 

“As I learned more and more about the technology, it became a passion of mine, as well,” said Confer. “What we’re trying to do in cancer – using a lipid-based delivery vehicle and working with tumor suppressor genes that are naturally occurring in the body – represents a treatment paradigm that is unique and different than other options in the space, particularly chemotherapy that has such negative side effects. It is something that we believe really has the potential to change people’s lives as they’re going through such a terrible prognosis. I was excited then, and here we are 12 years later, being able to see it coming through clinical trials, seeing how safe the program has been and seeing the impact that we’re having.”